Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2019-01-31416,2019,Adamson 2019 J Gen Intern Med,120000,"annual screening for melanoma VERSUS Annual screening for Melanoma, starting at age 60 IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; Annual screening starting at age 50.",31705474,"Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; Annual screening starting at age 50.",annual screening for melanoma,Screening for Melanoma in Men: a Cost-Effectiveness Analysis.,"Annual screening for Melanoma, starting at age 60",NE
2019-01-31416,2019,Adamson 2019 J Gen Intern Med,27000,"2 year-screening for melanoma VERSUS screening every 5 years, starting age 60 IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; screening every 2 years, starting age 60.",31705474,"Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; screening every 2 years, starting age 60.",2 year-screening for melanoma,Screening for Melanoma in Men: a Cost-Effectiveness Analysis.,"screening every 5 years, starting age 60",NE
2019-01-31416,2019,Adamson 2019 J Gen Intern Med,27000,"5-year screening for melanoma VERSUS None IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; screening every 5 years, starting age 60.",31705474,"Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; screening every 5 years, starting age 60.",5-year screening for melanoma,Screening for Melanoma in Men: a Cost-Effectiveness Analysis.,None,NE
2019-01-31416,2019,Adamson 2019 J Gen Intern Med,40000,"5-year screening for melanoma VERSUS screening every 5 years, starting age 60 IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; screening every 5 years, starting age 50.",31705474,"Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; screening every 5 years, starting age 50.",5-year screening for melanoma,Screening for Melanoma in Men: a Cost-Effectiveness Analysis.,"screening every 5 years, starting age 60",NE
2019-01-31416,2019,Adamson 2019 J Gen Intern Med,70000,"2 year-screening for melanoma VERSUS screening every 2 years, starting age 60 IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; screening every 2 years, starting age 50.",31705474,"Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; screening every 2 years, starting age 50.",2 year-screening for melanoma,Screening for Melanoma in Men: a Cost-Effectiveness Analysis.,"screening every 2 years, starting age 60",NE
2019-01-31416,2019,Adamson 2019 J Gen Intern Med,Dominated,"annual screening for melanoma VERSUS Screening every 2 years, starting age 50 IN Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; Annual screening starting at age 60.",31705474,"Healthy; Age- 41 to 64 years, >=65 years; Gender- Male; Country- United States; Other- white; Annual screening starting at age 60.",annual screening for melanoma,Screening for Melanoma in Men: a Cost-Effectiveness Analysis.,"Screening every 2 years, starting age 50",NW
2017-01-25353,2017,Gourzoulidis 2017 Clin Drug Investig,240,"Rivaroxaban VERSUS Standard/Usual Care- Enoxaparin/Vitamin K antagonist IN Specific disease- Pulmonary Embolism; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece; Other- Patients admitted to hospital with symptomatic venous thromboembolism event.",28608312,"Specific disease- Pulmonary Embolism; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece; Other- Patients admitted to hospital with symptomatic venous thromboembolism event.",Rivaroxaban,Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis  and Pulmonary Embolism in Greece.,Standard/Usual Care- Enoxaparin/Vitamin K antagonist,NE
2017-01-25353,2017,Gourzoulidis 2017 Clin Drug Investig,Cost-Saving,"Rivaroxaban VERSUS Standard/Usual Care- Enoxaparin/Vitamin K antagonist IN Specific disease- Deep Vein Thrombosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece; Other- Patients admitted to hospital with symptomatic venous thromboembolism event.",28608312,"Specific disease- Deep Vein Thrombosis; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Greece; Other- Patients admitted to hospital with symptomatic venous thromboembolism event.",Rivaroxaban,Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis  and Pulmonary Embolism in Greece.,Standard/Usual Care- Enoxaparin/Vitamin K antagonist,SE
2017-01-24342,2017,Tzanetakos 2017 Clin Drug Investig,3400,Exenatide Once Weekly VERSUS Standard/Usual Care- Liraglutide 1.2mg IN Specific disease- Type 2 Diabetes; Age- Adult; Gender- Both; Country- Greece.,29080210,Specific disease- Type 2 Diabetes; Age- Adult; Gender- Both; Country- Greece.,Exenatide Once Weekly,Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.,Standard/Usual Care- Liraglutide 1.2mg,NE
2017-01-24342,2017,Tzanetakos 2017 Clin Drug Investig,5400,Exenatide VERSUS Standard/Usual Care- Insulin glargine(IG) IN Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Greece.,29080210,Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Greece.,Exenatide,Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.,Standard/Usual Care- Insulin glargine(IG),NE
2016-01-21811,2016,Athanasakis                      2016 Clinicoecon Outcomes Res,2400,Eplerenone VERSUS Standard/Usual Care IN Specific disease- Chronic heart failure patients; Age- Adult; Gender- Both; Country- Greece; Other- New York Hear Association Class II with reduced left ventricular ejection fraction.,27785081,Specific disease- Chronic heart failure patients; Age- Adult; Gender- Both; Country- Greece; Other- New York Hear Association Class II with reduced left ventricular ejection fraction.,Eplerenone,Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients  with reduced LVEF: an analysis for Greece.,Standard/Usual Care,NE
2016-01-20082,2016,Sandhu 2016 JACC Heart Fail,52000,"CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure VERSUS Standard/Usual Care IN Specific disease- chronic heart failure (CHF); Age- Adult; Gender- Both; Country- United States; Other- CHARM (Candesartan in Heart failure: Reduction in Mortality and Morbidity) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with preserved ejection fraction (21.7%).",26874380,Specific disease- chronic heart failure; Age- Adult; Gender- Both; Country- United States; Other- CHARM (Candesartan in Heart failure: Reduction in Mortality and Morbidity) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with preserved ejection fraction (21.7%).,"CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure",Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure.,Standard/Usual Care,NE
2016-01-20082,2016,Sandhu 2016 JACC Heart Fail,78000,"CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure VERSUS Standard/Usual Care IN Specific disease- chronic heart failure (CHF); Age- Adult; Gender- Both; Country- United States; Other- CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with preserved ejection fraction (21.7%) or reduced ejection fraction (78.3%).",26874380,Specific disease- chronic heart failure; Age- Adult; Gender- Both; Country- United States; Other- CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with preserved ejection fraction (21.7%) or reduced ejection fraction (78.3%).,"CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure",Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure.,Standard/Usual Care,NE
2016-01-20082,2016,Sandhu 2016 JACC Heart Fail,90000,"CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure VERSUS Standard/Usual Care IN Specific disease- chronic heart failure (CHF); Age- Adult; Gender- Both; Country- United States; Other- CHARM (Candesartan in Heart failure: Reduction in Mortality and Morbidity) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with reduced ejection fraction (78.3%).",26874380,Specific disease- chronic heart failure; Age- Adult; Gender- Both; Country- United States; Other- CHARM (Candesartan in Heart failure: Reduction in Mortality and Morbidity) cohort; New York Heart Association (NYHA) Class III Heart Failure Patients; hospitalized within 1 year with reduced ejection fraction (78.3%).,"CardioMEMS device placement, an implantable, wireless pulmonary artery pressure monitoring system to decrease hospitalizations related to heart failure",Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure.,Standard/Usual Care,NE
2016-01-19662,2016,Kourlaba 2016 Cost Eff Resour Alloc,Cost-Saving,"ranibizumab 0.5 mg (pro re nata) VERSUS aflibercept IN Specific disease- diabetic macular edema; Age- Adult; Gender- Both; Country- Greece; Other- general population of patients with visual impairmen(VI) due to diabetic macular edema(DME). At least one eye with a Best Corrected Visual Acuity (BCVA) score between 78 and 39 letters,.",27081372,"Specific disease- diabetic macular edema; Age- Adult; Gender- Both; Country- Greece; Other- general population of patients with visual impairmen(VI) due to diabetic macular edema(DME). At least one eye with a Best Corrected Visual Acuity (BCVA) score between 78 and 39 letters,.",ranibizumab 0.5 mg (pro re nata),Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema.,aflibercept,SE
2016-01-19662,2016,Kourlaba 2016 Cost Eff Resour Alloc,Cost-Saving,ranibizumab 0.5 mg treat and extend (RAN T&E) VERSUS alibercept 2 mg (every 8 weeks after initial doses) IN Specific disease- diabetic macular edema; Age- Adult; Gender- Both; Country- Greece; Other- general population of patients with visual impairmen(VI) due to diabetic macular edema(DME). at least one eye with a Best Corrected Visual Acuity (BCVA) score between 78 and 39 letters.,27081372,Specific disease- diabetic macular edema; Age- Adult; Gender- Both; Country- Greece; Other- general population of patients with visual impairmen(VI) due to diabetic macular edema(DME). at least one eye with a Best Corrected Visual Acuity (BCVA) score between 78 and 39 letters.,ranibizumab 0.5 mg treat and extend (RAN T&E),Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema.,alibercept 2 mg (every 8 weeks after initial doses),SE
2016-01-19558,2016,Rothschild 2016 Am J Ophthalmol,Cost-Saving,"100% screening coverage + standard care VERSUS Standard/Usual Care- Current levels of screening and treatment of retinopathy of prematurity (52%) IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Mexico; Other- Low birth weight infants weighing <1500 g, at risk of having retinopathy of prematurity.",27130372,"Healthy; Age- 0 to 18 years; Gender- Both; Country- Mexico; Other- Low birth weight infants weighing <1500 g, at risk of having retinopathy of prematurity.",100% screening coverage + standard care,The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States.,Standard/Usual Care- Current levels of screening and treatment of retinopathy of prematurity (52%),SE
2016-01-19558,2016,Rothschild 2016 Am J Ophthalmol,Cost-Saving,"100% screening coverage + standard care VERSUS Standard/Usual Care- current levels of screening and treatment of retinopathy of prematurity (52%) IN Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- Low birth weight infants weighing <1500 g, at risk of having retinopathy of prematurity.",27130372,"Healthy; Age- 0 to 18 years; Gender- Both; Country- United States; Other- Low birth weight infants weighing <1500 g, at risk of having retinopathy of prematurity.",100% screening coverage + standard care,The Economic Model of Retinopathy of Prematurity (EcROP) Screening and Treatment: Mexico and the United States.,Standard/Usual Care- current levels of screening and treatment of retinopathy of prematurity (52%),SE
2016-01-19389,2016,Tzanetakos 2016 Clin Drug Investig,13000,Dapagliflozin (average daily dose of 10mg) and metformin VERSUS Sulfonylurea (SU) and metformin IN Specific disease- Type 2 Diabetes Mellitus (T2DM); Age- Adult; Gender- Both; Country- Greece.,27221806,Specific disease- type 2 diabetes (T2DM); Age- Adult; Gender- Both; Country- Greece.,Dapagliflozin (average daily dose of 10mg) and metformin,Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.,Sulfonylurea (SU) and metformin,NE
2016-01-19389,2016,Tzanetakos 2016 Clin Drug Investig,21000,Dapagliflozin (average daily dose of 10mg) and metformin VERSUS dipeptidyl peptidase-4 inhibitor (DPP-4i) + metformin IN Specific disease- Type 2 Diabetes Mellitus (T2DM); Age- Adult; Gender- Both; Country- Greece.,27221806,Specific disease- type 2 diabetes (T2DM); Age- Adult; Gender- Both; Country- Greece.,Dapagliflozin (average daily dose of 10mg) and metformin,Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.,dipeptidyl peptidase-4 inhibitor (DPP-4i) + metformin,NE
1 2 3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
